Mark Sard

Director/Miembro de la Junta en LIRUM THERAPEUTICS, INC. .

61 años

Health Technology

Consumer Services

Finance

Perfil

Mark Sard is the founder.
He founded Frontier Equities VC LLC in 2011 as a Principal.
He is currently working as a Director at Lirum Therapeutics, Inc. since 2022.
Previously, he worked as a Director at Stemline Therapeutics, Inc. from 2018 to 2020.
Mr. Sard completed his undergraduate degree at the University of Pennsylvania.

Cargos activos de Mark Sard

Empresas	Cargo	Inicio
LIRUM THERAPEUTICS, INC.	Director/Miembro de la Junta	01/11/2022
Frontier Equities VC LLC Frontier Equities VC LLC Investment ManagersFinance Frontier Equities seeks investment opportunities in early to mid-stage companies located in United States. The firm focuses across a wide array of sectors.	Fundador	01/01/2011

Todos los cargos activos de Mark Sard

Antiguos cargos conocidos de Mark Sard.

Empresas	Cargo	Fin
STEMLINE THERAPEUTICS, INC.	Director/Miembro de la Junta	10/06/2020

Ver el detalle de la experiencia de Mark Sard.

Formación de Mark Sard.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Mark Sard.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	4
Stemline Therapeutics, Inc. Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel oncology therapeutics	Health Technology
University of Pennsylvania University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Frontier Equities VC LLC Frontier Equities VC LLC Investment ManagersFinance Frontier Equities seeks investment opportunities in early to mid-stage companies located in United States. The firm focuses across a wide array of sectors.	Finance
Lirum Therapeutics, Inc. Lirum Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that focuses on the treatment of debilitating diseases	Health Technology